Enterprise Value
0.00
Cash
1.404M
Avg Qtr Burn
-3.186M
Short % of Float
0.00%
Insider Ownership
0.80%
Institutional Own.
0.03%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Leronlimab Details Non-alcoholic steatohepatitis | Phase 2/3 Update | |
Leronlimab Details Solid tumor/s, Cancer | Phase 2 Update | |
Leronlimab (PRO 140) Details Human immunodeficiency virus | Phase 2 Update | |
Leronlimab Details Graft-versus-host disease | Failed Discontinued | |
Leronlimab (PRO 140) Details COVID-19 | Failed Discontinued |